– USA, MA – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors.
“We are excited to welcome Darlene to our Board of Directors at this important time in our company,” said CEO, David de Graaf. “Darlene brings an impressive, thirty-year track record working with both publicly traded and venture-backed life sciences companies to Abcuro. Her insights will be invaluable as we continue to advance the clinical development of ABC008 and expand our therapeutic pipeline. We look forward to working with Darlene in developing capital market options and potential partnerships.”
About Darlene Deptula-Hicks
Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies.
Ms. Deptula-Hicks is recognized for her breadth of expertise in growth strategies and success at capital raising and IPOs. She operates Crimson Advisors, LLC, a strategic financial consulting services company, and currently serves as the CFO of F-star Therapeutics, Inc. (NASDAQ: FSTX) which she took public in 2020. She provides strategic financial and business direction and leadership on long-term strategies and decisions affecting the future financial performance of organizations including capital formation, commercialization, strategy, and M&A. Previously, she was CFO of Northern Biologics, Inc., and T2 Biosystems, Inc. (NASDAQ: TTOO). She also served as SVP and CFO of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) which she also took public. Ms. Deptula-Hicks received her M.B.A. from Rivier University and B.S in accounting from Southern New Hampshire University.
“I am excited to join Abcuro’s Board and help further grow the company as they develop potentially life-changing medicines,” said Ms. Deptula-Hicks. “I look forward to contributing to Abcuro’s success and bringing value to investors, potential partners, and of course, patients.”
About Abcuro
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company’s lead program is ABC008, which is currently in clinical trials for inclusion body myositis (IBM). ABC008 is also advancing into clinical trials for additional autoimmune disease indications. The company is also developing ABC015 to selectively activate highly cytotoxic T and NK cells for treating cancer.
For more information: https://abcuro.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.